# Freenome

Canonical page: https://technooptimist.io/companies/freenome
Brisbane, California company that reads DNA methylation and other signals in blood to screen for cancer. Its colorectal test SimpleScreen won FDA approval in July 2026 and is sold by Abbott.

## In brief

- SimpleScreen CRC: FDA approved 27 Jul 2026 for average-risk adults 45+, the second blood test after Guardant's Shield.
- Abbott (which bought Exact Sciences) sells it in the US; deal worth up to $885M to Freenome.
- Listed on Nasdaq (FRNM) in July 2026 via a SPAC, raising about $310M.

## Facts

- Headquarters: US
- Status: public
- Website: https://www.freenome.com
- Frontiers: [Biotech](https://technooptimist.io/biotech.md) (Cancer DNA tests)

## Programs

- [SimpleScreen CRC](https://technooptimist.io/biotech/simplescreen-crc.md) (Biotech): Deploy; next: Abbott US commercial launch (Q4 2026). FDA approved July 2026; Abbott launching in the US this autumn; upgraded version to follow.

## Latest updates

- **27 Jul 2026**: FDA approves Freenome's SimpleScreen CRC blood test; Abbott to market it in the US. The FDA approved SimpleScreen CRC for average-risk adults aged 45 and older, making it the second blood-based colorectal screening test after Guardant Health's Shield. ([our story](https://technooptimist.io/stories/fda-approves-freenome-s-simplescreen-crc-blood-test-abbott-to-market-it-65f898d2.md) · [original source](https://medtechdive.com/news/freenome-secures-fda-nod-for-blood-based-colorectal-cancer-test/826290))
- **23 Jul 2026**: Freenome lists on Nasdaq through a SPAC merger, raising about $310M. Freenome completed its merger with Perceptive Capital Solutions Corp. ([our story](https://technooptimist.io/stories/freenome-lists-on-nasdaq-through-a-spac-merger-raising-about-310m-9e293e63.md) · [original source](https://www.goodwinlaw.com/en/news-and-events/news/2026/07/announcements-lifesciences-spac-goodwin-advised-freenome-business-combination-310m-financing))
- **6 Aug 2025**: Freenome licenses its colorectal blood test to Exact Sciences in a deal worth up to $885M. Freenome gave Exact Sciences, maker of the Cologuard stool test, exclusive rights to sell its blood-based colorectal screening test, and submitted the final module of its FDA application. ([our story](https://technooptimist.io/stories/freenome-licenses-its-colorectal-blood-test-to-exact-sciences-in-a-deal-5f1df735.md) · [original source](https://www.freenome.com/newsroom/freenome-announces-exclusive-license-agreement-with-exact-sciences-to-commercialize-freenomes-blood-based-screening-test-for-colorectal-cancer/))

## Funding

| Date | Round | Amount | Post-money | Leads |
| --- | --- | --- | --- | --- |
| Jul 2026 | SPAC merger + PIPE | $310M |   | Perceptive Advisors, RA Capital |

## Partners, customers and investors

- Abbott (partner): Exclusive US marketer of SimpleScreen CRC, via the license first signed with Exact Sciences in Aug 2025.

## People

- Aaron Elliott, Chief Executive Officer
- Riley Ennis, Co-founder, Chief Product Officer

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.